Virtual colonoscopy and contrast developer E-Z-EM of Lake Success, NY, has inked a deal with Berlex Laboratories, a U.S. subsidiary of Berlin-based Schering, for Berlex’s x-ray diagnostic contrast agent Ultravist (iopromide).
Under the terms of the agreement, E-Z-EM will promote Ultravist to a targeted list of CT facilities in the U.S. and Berlex will pay E-Z-EM a co-promotion royalty on sales to its target customers. The five-year agreement is effective as of this month, the companies said.
By AuntMinnie.com staff writersJuly 15, 2003
Related Reading
E-Z-EM to close New York and Puerto Rico operations, June 2, 2003
E-Z-EM, 3CPM sign agreement, April 17, 2003
E-Z-EM shows sales growth in Q3, April 15, 2003
E-Z-EM and JPC ink multiyear deal, April 10, 2003
E-Z-EM closes deal with MAGNET, March 19, 2003
Copyright © 2003 AuntMinnie.com
